Abstract:The very high energy demand of the heart is primarily met by ATP production from mitochondrial oxidative phosphorylation, with glycolysis providing a smaller amount of ATP production. This ATP production is markedly altered in heart failure, primarily due to a decrease in mitochondrial oxidative metabolism. Although an increase in glycolytic ATP production partly compensates for the decrease in mitochondrial ATP production, the failing heart faces an energy deficit, that contributes to the severity of contractile dysfunction. The relative contribution of the different fuels for mitochondrial ATP production dramatically changes in the failing heart, which depends to a large extent on the type of heart failure. A common metabolic defect in all forms of heart failure (including HFrEF, HFpEF, and diabetic cardiomyopathies) is a decrease in mitochondrial oxidation of pyruvate originating from glucose (i.e. glucose oxidation). This decrease in glucose oxidation occurs regardless of whether glycolysis is increased, resulting in an uncoupling of glycolysis from glucose oxidation that can decrease cardiac efficiency. The mitochondrial oxidation of fatty acids by the heart increases or decreases, depending on the type of heart failure. For instance, in HFpEF and diabetic cardiomyopathies myocardial fatty acid oxidation increases, while in HFrEF myocardial fatty acid oxidation either decreases or remains unchanged. The oxidation of ketones (which provides the failing heart with an important energy source) also differs depending on the type of heart failure, being increased in HFrEF, and decreased in HFpEF and diabetic cardiomyopathies. The alterations in mitochondrial oxidative metabolism and glycolysis in the failing heart are due to transcriptional changes in key enzymes involved in the metabolic pathways, as well as alterations in redox state, metabolic signaling, and posttranslational epigenetic changes in energy metabolic enzymes. Of importance, targeting the mitochondrial energy metabolic pathways has emerged as a novel therapeutic approach to improving cardiac function and cardiac efficiency in the failing heart.

Integrated Control of Fatty Acid Metabolism in Heart Failure

Research Progress on the Metabolic Remodeling of Myocardial Energy Substrate in Heart Failure

Deranged Myocardial Fatty Acid Metabolism in Heart Failure

The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases

Ketone Body Metabolism in Diabetic and Non-Diabetic Heart Failure.

Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure

Metabolic Disorder in the Progression of Heart Failure.

Metabolic remodeling of substrate utilization during heart failure progression

Energy metabolism and redox balance: How phytochemicals influence heart failure treatment

Advances in myocardial energy metabolism: metabolic remodeling in heart failure and beyond

Lipid metabolism and signaling in cardiac lipotoxicity

Fatty acid metabolism disorders and potential therapeutic traditional Chinese medicines in cardiovascular diseases

Cardiac Energy Metabolism in Heart Failure

Insights into the post-translational modifications in heart failure

Gut-derived short-chain fatty acids bridge cardiac and systemic metabolism and immunity in heart failure

Energy metabolism disorders and potential therapeutic drugs in heart failure

Abstract 9485: Role of Fatty Acid Oxidation in Heart Function

Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets

Novel insights into the involvement of mitochondrial fission/fusion in heart failure: From molecular mechanisms to targeted therapies

Mitochondrial Dysfunction in Heart Failure and Its Therapeutic Implications

Leveraging metabolism for better outcomes in heart failure